Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation

References

• Wigle P, Hein B, Bloomfield HE, et al. Updated guidelines on outpatient anticoagulation. Am Fam Physician. 2013;87(8):556–566.
   PubMed Web of Science ®Google Scholar
• Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94.
   PubMedGoogle Scholar
• Burgazli KM, Atmaca N, Mericliler M, et al. Deep vein thrombosis and novel oral anticoagulants: a clinical review. Eur Rev Med Pharmacol Sci. 2013;17(23):3123–3131.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Sardar P, Chatterjee S, Lavie CJ, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2014 ;20(179):279–287.
   Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975–986.
   PubMed Web of Science ®Google Scholar
• Saji N, Kimura K, Tateishi Y, et al. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study). J Thromb Thrombolysis. 2016;42(4):453–462.
   PubMed Web of Science ®Google Scholar
• Saji N, Kimura K, Aoki J, et al. Intracranial hemorrhage caused by non-vitamin K antagonist oral anticoagulants (NOACs) – multicenter retrospective cohort study in Japan. Circ J. 2015;79(5):1018–1023.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Vilchez JA, Gallego P, Lip GY. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf. 2014;5(1):8–20.
   PubMedGoogle Scholar
• European-Medicines-Agency-(EMA). Eliquis (R). Apixaban summary of product characteristics. [cited 2017 Apr 24]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
   Google Scholar
• European-Medicines-Agency-(EMA). Lixiana (R). Edoxaban summary of product characteristics. [cited 2017 Apr 24]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf.
   Google Scholar
• European-Medicines-Agency-(EMA). Pradaxa (R). Dabigatran summary of product characteristics. [cited 2017 Apr 24]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
   Google Scholar
• European-Medicines-Agency-(EMA). Xarelto (R). Rivaroxaban summary of product characteristics. [cited 2017 Apr 24]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
   Google Scholar
• Ageno W, Buller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost. 2016;116(6):1003–1010.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis–task force on anticoagulants in heart disease. Thromb Haemost. 2013;110(6):1087–1107.
   PubMed Web of Science ®Google Scholar
• Van Den Ham HA, Klungel OH, Leufkens HG, et al. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost. 2013;11(1):107–115.
   PubMed Web of Science ®Google Scholar
• Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016;11(10):e0164076.
   PubMed Web of Science ®Google Scholar
• Bertomeu-Gonzalez V, Anguita M, Moreno-Arribas J, et al. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol. 2015;38(6):357–364.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–977.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost. 2015;113(4):671–673.
   PubMed Web of Science ®Google Scholar
• Lip GY, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604.
   PubMed Web of Science ®Google Scholar
• Bell AD, Gross P, Heffernan M, et al. Appropriate use of antithrombotic medication in Canadian patients with nonvalvular atrial fibrillation. Am J Cardiol. 2016;117(7):1107–1111.
   PubMed Web of Science ®Google Scholar
• Basaran O, Filiz Basaran N, Cekic EG, et al. PRescriptiOn PattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost. 2017;23(4):384–391.
   PubMed Web of Science ®Google Scholar
• Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183–200.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Verdecchia P, Giustozzi M, et al. Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. Int J Cardiol. 2017;236:363–369.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63(4):321–328.
   PubMed Web of Science ®Google Scholar
• Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med. 2016;129(11):1198–1204.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Fernandez H, et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111(8):1159–1164.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2(6):e000535.
   PubMed Web of Science ®Google Scholar
• Dobesh PP, Direct Oral FJ. Anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities. Drugs. 2015;75(14):1627–1644.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Administration UFD. Briefing information for the October 30, 2014, Meeting of the Cardiovascular and Renal Drugs Advisory Committee 2014 [cited 2017 10/05/2017]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm420703.htm.
   Google Scholar
• Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016;1(4):451–460.
   PubMed Web of Science ®Google Scholar
• Hu HH, Sheng WY, Chu FL, et al. Incidence of stroke in Taiwan. Stroke. 1992;23(9):1237–1241.
   PubMed Web of Science ®Google Scholar
• Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–315.
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–2307.
   PubMed Web of Science ®Google Scholar
• Chao TF, Liu CJ, Tuan TC, et al. Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: a nationwide cohort study. Mayo Clin Proc. 2016;91(5):567–574.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Popescu MI, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF general pilot registry. Europace. 2015;17(12):1777–1786.
   PubMed Web of Science ®Google Scholar
• Diez-Manglano J, Gomes-Martin J, Al-Cheikh-Felices P, et al. Adherence to guidelines and mortality in atrial fibrillation. Int J Cardiol. 2014;176(2):430–436.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.e4.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–2448.
   PubMed Web of Science ®Google Scholar
• Själander S, Själander A, Svensson PJ, et al. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16(5):631–638.
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefevre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6(9):e011471.
   PubMed Web of Science ®Google Scholar
• Sabouret P, Bricard M, Hermann MA, et al. Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. Arch Cardiovasc Dis. 2015;108(11):544–553.
   PubMed Web of Science ®Google Scholar
• Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: the BALKAN-AF Survey. Sci Rep. 2016;6:20432.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.
   PubMed Web of Science ®Google Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99(16):1166–1172.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med. 2014;127(6):519–29.e1.
   PubMed Web of Science ®Google Scholar
• Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, phase II. Am J Med. 2015;128(12):1306–13.e1.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55–62.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Villejoubert O, Clementy N, et al. Causes of deaths and influencing factors in patients with atrial fibrillation. Am J Med. 2016;129(12):1278–1287.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Lip GY. Registries in atrial fibrillation: from trials to real-life clinical practice. Am J Med. 2017;130(2):135–145.
   PubMed Web of Science ®Google Scholar
• Kachroo S, Hamilton M, Liu X, et al. Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation. Am J Manag Care. 2016;22(1):e1–8.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016;115(1):31–39.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209–218.
   PubMed Web of Science ®Google Scholar
• Obamiro KO, Chalmers L, Bereznicki LR. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 2016;16(5):349–363.
   PubMed Web of Science ®Google Scholar
• Cerasuolo JO, Montero-Odasso M, Ibanez A, et al. Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. Int J Stroke. 2017;12(3):222–228.
   PubMed Web of Science ®Google Scholar
• Jespersen SF, Christensen LM, Christensen A, et al. Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry. Thrombosis. 2013;2013:601450.
   PubMedGoogle Scholar
• Lopes RD, Shah BR, Olson DM, et al. Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL registry. Stroke. 2011;42(12):3477–3483.
   PubMed Web of Science ®Google Scholar
• Vallakati A, Lewis WR. Underuse of anticoagulation in patients with atrial fibrillation. Postgrad Med. 2016;128(2):191–200.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–837.
   PubMed Web of Science ®Google Scholar
• Bahri O, Roca F, Lechani T, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–76.
   PubMed Web of Science ®Google Scholar
• Annoni G, Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol. 2016;13(3):226–232.
   PubMedGoogle Scholar
• Garkina SV, Vavilova TV, Lebedev DS, et al. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol. 2016;13(9):807–810.
   PubMedGoogle Scholar
• Pipilis A, Farmakis D, Kaliambakos S, et al. Anticoagulation therapy in elderly patients with atrial fibrillation: results from the registry of atrial fibrillation to investigate the implementation of new guidelines (RAFTING). J Cardiovasc Med. 2017;18(7):545–549.
   Google Scholar
• Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999–1002.
   PubMed Web of Science ®Google Scholar
• Chang SS, Dong JZ, Ma CS, et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese atrial fibrillation registry study. Stroke. 2016;47(7):1803–1810.
   PubMed Web of Science ®Google Scholar
• Lefebvre MC, St-Onge M, Glazer-Cavanagh M, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32(2):169–176.
   PubMed Web of Science ®Google Scholar
• Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46(1):143–150.
   PubMed Web of Science ®Google Scholar
• Syed YY. Idarucizumab: a review as a reversal agent for dabigatran. Am J Cardiovasc Drugs. 2016;16(4):297–304.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520.
   PubMed Web of Science ®Google Scholar
• Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ. 2017;357:j2216.
   PubMed Web of Science ®Google Scholar
• Roldan I, Marin F. On the way to a better use of anticoagulants in nonvalvular atrial fibrillation. Proposed amendment to the therapeutic positioning report UT/V4/23122013. Rev Esp Cardiol (Engl Ed). 2016;69(6):551–553.
   PubMed Web of Science ®Google Scholar
• Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016;14(9):1711–1714.
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost. 2015;114(4):819–825.
   PubMed Web of Science ®Google Scholar
• Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015;351:h5876.
   PubMed Web of Science ®Google Scholar
• Witt DM, Clark NP, Martinez K, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thromb Res. 2015;136(5):1040–1044.
   PubMed Web of Science ®Google Scholar
• Molina CA, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke. 2011;42(12):3665–3666.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost. 2014;111(1):14–18.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Larsen TB, Skjoth F, et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation. 2015;132(6):517–525.
   PubMed Web of Science ®Google Scholar
• Proietti M, Nobili A, Raparelli V, et al. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol. 2016;105(11):912–920.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153(6):1006–1012.
   PubMed Web of Science ®Google Scholar
• Gorin L, Fauchier L, Nonin E, et al. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest. 2011;140(4):911–917.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29(8):675–690.
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–523.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Komocsi A. Discontinuation of anticoagulant treatment: from clinical trials to medication persistence. Curr Med Res Opin. 2015;31(10):1841–1844.
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjoth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–1299.
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration. Am Heart J. 2014;167(6):810–817.
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72(3):329–338.
   PubMed Web of Science ®Google Scholar
• Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm. 2015;31(6):339–344.
   PubMed Web of Science ®Google Scholar
• Al-Khalili F, Lindstrom C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin. 2016;32(4):779–785.
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2016;22(11):1319–1329.
   PubMedGoogle Scholar
• Emren SV, Senoz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey. Clin Appl Thromb Hemost. 2017. 1076029617693940.
   PubMedGoogle Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115(5):939–949.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS One. 2016;11(6):e0157769.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Kilickiran Avci B, Vatan B, Ozden Tok O, et al. The trends in utilizing nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a real-life experience. Clin Appl Thromb Hemost. 2016;22(8):785–791.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol. 2016;212:171–173.
   PubMed Web of Science ®Google Scholar
• Nishino M, Okamoto N, Tanaka A, et al. Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban. J Cardiol. 2016;68(2):156–160.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Peterson ED, Laliberte F, et al. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. Clin Ther. 2016;38(11):2477–2488.
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015;31(10):1889–1895.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016;215:11–13.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberte F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin. 2015;31(12):2167–2173.
   PubMed Web of Science ®Google Scholar
• Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015;136(4):727–731.
   PubMed Web of Science ®Google Scholar
• Königsbrügge O, Simon A, Domanovits H, et al. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. BMC Cardiovasc Disord. 2016;16(1):254.
   PubMed Web of Science ®Google Scholar
• Shahid F, Shantsila E. Lip GYH. What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation? Eur Heart J Supplements. 2016;18(suppl_I):I18–I24.
   Web of Science ®Google Scholar
• Amin A, Marrs JC. Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost. 2016;22(7):605–616.
   PubMed Web of Science ®Google Scholar
• Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010;4:51–60.
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015;17(4):507–508.
   PubMed Web of Science ®Google Scholar
• Amara W, Larsen TB, Sciaraffia E, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2016;18(1):151–155.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117:1448–1454.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016; 5(2)
   Web of Science ®Google Scholar
• Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015;46(1):23–30.
   PubMed Web of Science ®Google Scholar
• Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2013;61(6):651–658.
   PubMed Web of Science ®Google Scholar
• Vene N, Mavri A, Gubensek M, et al. Risk of thromboembolic events in patients with non-valvular atrial fibrillation after dabigatran or rivaroxaban discontinuation – data from the ljubljana registry. PLoS One. 2016;11(6):e0156943.
   PubMed Web of Science ®Google Scholar
• Rubboli A. Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Curr Med Res Opin. 2015;31(10):1845–1847.
   PubMed Web of Science ®Google Scholar
• Loewen PS, Ji AT, Kapanen A, et al. Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review. Thromb Haemost. 2017;117:1007–1022.
   PubMed Web of Science ®Google Scholar
• Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38:860–868.
   Google Scholar